Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. [electronic resource]
Producer: 20080918Description: 2528-37 p. digitalISSN:- 0004-3591
- Adult
- Aged
- Benzamides
- Biopsy
- Case-Control Studies
- Cells, Cultured
- Connective Tissue Growth Factor
- Female
- Fibroblasts -- drug effects
- Humans
- Imatinib Mesylate
- Immediate-Early Proteins -- metabolism
- Intercellular Signaling Peptides and Proteins -- metabolism
- Male
- Middle Aged
- Mitogen-Activated Protein Kinase 1 -- metabolism
- Mitogen-Activated Protein Kinase 3 -- metabolism
- Piperazines -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Pyrimidines -- pharmacology
- Scleroderma, Systemic -- drug therapy
- Signal Transduction -- drug effects
- Skin -- drug effects
- Smad1 Protein -- drug effects
- Transforming Growth Factor beta -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.